Wilmington, DE, United States of America

Sean M Dalziel

This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Dairy Australia Limited, E.i. Dupont De Nemours and Company. Active years: 2007-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sean M Dalziel. Retrieved from https://idiyas.com/inventor/sean-m-dalziel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

 


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 2007-2010

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Sean M Dalziel: Innovator in Pharmaceutical Compounds

Introduction

Sean M Dalziel is a notable inventor in the field of pharmaceuticals, particularly recognized for his work on benzimidazole-carboxamide compounds. His innovative contributions focus on the development of compounds that act as 5-HT4 receptor agonists, which have potential therapeutic applications.

Latest Patents

Sean M Dalziel holds a patent related to "Benzimidazole-Carboxamide Compounds As 5-Ht4 Receptor Agonists." This invention pertains to compounds of formula (I), where R1 and X are defined in the specification. The patent also covers pharmaceutically acceptable salts, solvates, or stereoisomers of these compounds. Additionally, it includes pharmaceutical compositions that comprise such compounds, methods for treating diseases associated with 5-HT4 receptor activity, and processes for preparing these compounds. Furthermore, the invention discusses crystalline forms of the compound of formula (I).

Career Highlights

Sean M Dalziel is currently associated with Theravance, Inc., where he continues to contribute to the advancement of pharmaceutical innovations. His work is pivotal in exploring new therapeutic avenues for various medical conditions.

Collaborations

Sean has collaborated with notable colleagues, including Robert Murray Mckinnell and Roland Gendron, who share a commitment to advancing pharmaceutical research and development.

Conclusion

Sean M Dalziel's contributions to the field of pharmaceuticals, particularly through his innovative work on 5-HT4 receptor agonists, highlight his role as a significant inventor. His ongoing efforts at Theravance, Inc. continue to pave the way for new therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…